Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare Disease Patients: Placebo Controls, Sham Surgeries Not Appropriate For Gene Therapy Trials

Executive Summary

Advocates also worry that long follow-up times could prevent participation in future clinical trials.

You may also be interested in...

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

A recent externally-led PFDD meeting on kidney xenotransplantation, rather than a specific disease, allowed for more tailored patient comments on the procedure, which could impact development plans going forward.

Gene Therapies Without Randomized Clinical Trials: Marks Outlines Rare Disease Development Path

A single-arm trial using a biomarker and animal model could be enough for an accelerated approval, especially in a pediatric rare disease where randomization and placebo controls may not be feasible, the CBER director said.

CMS Seeking Patient Comments On Negotiated Drugs Similar To US FDA’s PFDD Program

Statements on patient experience with the diseases treated by the drugs subject to price negotiation and how they impact their lives are requested; 10 meetings are planned for the fall.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts